Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: Results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial

British Journal of Dermatology

Volumn 170, Issue 1, 2014, Pages 173-181

  Vahlquist, A ^a   Blockhuys, S ^b   Steijlen, P ^c   Van Rossem, K ^d   Didona, B ^e   Blanco, D ^f   Traupe, H ^g  

^a UPPSALA UNIVERSITY   (Sweden)

^b ABLYNX NV   (Belgium)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Stiefel Laboratories Inc   (United States)

^e LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^f Instituto Dermatolõgico   (Dominican Republic)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; IMMUNOGLOBULIN A; LIAROZOLE; DERMATOLOGICAL AGENT; IMIDAZOLE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; BODY MASS; CHEILITIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAM; EPISTAXIS; ERYTHEMA; EYE DISEASE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERHIDROSIS; INTENTION TO TREAT ANALYSIS; LAMELLAR ICHTHYOSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHORT FORM 36; SKIN EXFOLIATION; SKIN MANIFESTATION; VITAL SIGN; YOUNG ADULT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; ICHTHYOSIS, LAMELLAR; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ICHTHYOSIS, LAMELLAR; IMIDAZOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892406437     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12626     Document Type: Article

References (17)

1. Oji V, Tadini G, Akiyama M, et al,. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. J Am Acad Dermatol 2010; 63: 607-41.
2. Vahlquist A, Ganemo A, Virtanen M,. Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol 2008; 88: 4-14.
3. Oji V, Traupe H,. Ichthyoses: differential diagnosis and molecular genetics. Eur J Dermatol 2006; 16: 349-59.
4. Hernandez-Martin A, Garcia-Doval I, Aranegui B, et al,. Prevalence of autosomal recessive congenital ichthyosis: a population-based study using the capture-recapture method in Spain. J Am Acad Dermatol 2012; 67: 240-4.
5. Ganemo A, Lindholm C, Lindberg M, et al,. Quality of life in adults with congenital ichthyosis. J Adv Nurs 2003; 44: 412-19.
6. Kamalpour L, Gammon B, Chen KH, et al,. Resource utilization and quality of life associated with congenital ichthyoses. Pediatr Dermatol 2011; 28: 512-18.
7. Summary of Product Characteristics, 2011. Neotigason 10 mg capsules. Available at: http://www.medicines.org.uk/emc/medicine/21212/SPC/ Neotigason+10&x00A0;mg+Capsules/ (last accessed 23 October 2013).
8. Medication guide for patients. Soriatane capsules, 2011. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089133.pdf (last accessed 23 October 2013).
9. Barrier Therapeutics, Inc. Barrier Therapeutics granted European orphan drug status for liarozole, 2003. Available at: http://www.prnewswire.com/news- releases/71303547.html (last accessed 23 October 2013).
10. Barrier Therapeutics, Inc. Barrier Therapeutics' liarozole receives FDA orphan drug status, 2004. Available at: http://www.prnewswire.com/news-releases/ barrier-therapeutics-liarozole-receives-fda-orphan-drug-status-75105912.html (last accessed 23 October 2013).
11. Verfaille CJ, Borgers M, van Steensel MA,. Retinoic acid metabolism blocking agents (RAMBAs): a new paradigm in the treatment of hyperkeratotic disorders. J Dtsch Dermatol Ges 2008; 6: 355-64.
12. Lucker GP, Heremans AM, Boegheim PJ, et al,. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 1997; 136: 71-5.
13. Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C, et al,. Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study. Br J Dermatol 2007; 156: 965-73.
14. World Medical Association. World Medical Association Declaration of Helsinki; ethical principles for medical research involving human subjects, 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/17c.pdf (last accessed 23 October 2013).
15. Ware JE Jr,. SF-36 health survey update. Spine (Phila Pa 1976) 2000; 25: 3130-9.
16. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
17. Lewis V, Finlay AY,. 10 years' experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-80.